Navigation Links
Liver Fibrosis-Pipeline Insights, 2014
Date:9/3/2014

NEW YORK, Sept. 3, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Liver Fibrosis-Pipeline Insights, 2014

http://www.reportlinker.com/p02278629/-Liver-Fibrosis-Pipeline-Insights-2014.html

SUMMARY
DelveInsight's," Liver Fibrosis-Pipeline Insights, 2014", report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Liver Fibrosis. This report provides information on the therapeutic development based on the Liver Fibrosis dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.
Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated Indication.

Scope
- The report provides a snapshot of the global therapeutic landscape of Liver Fibrosis
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Liver Fibrosis pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Liver Fibrosis and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


Reasons to buy
- Complete Pipeline intelligence and complete understanding over therapeutics development for Liver Fibrosis
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Liver Fibrosis pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions
Table of Contents
- Liver Fibrosis Overview
- Liver Fibrosis Pipeline Therapeutics
- Liver Fibrosis Therapeutics under Development by Companies
- Liver Fibrosis Late Stage Products (Filed and Phase III)
- Comparative Analysis
- Liver Fibrosis Mid Clinical Stage Products (Phase II)
- Comparative Analysis
- Liver Fibrosis Early Clinical Stage Products (Phase I and IND Filed)
- Comparative Analysis
- Liver Fibrosis Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Liver Fibrosis – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Liver Fibrosis – Discontinued Products
- Liver Fibrosis – Dormant Products
- Companies Involved in Therapeutics Development for Liver Fibrosis
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Liver Fibrosis, 2014
- Number of Products under Development by Companies
- Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
- Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
- Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
- Drug Candidates Profiles
- Liver Fibrosis Assessment by Monotherapy Products
- Liver Fibrosis Assessment by Combination Products
- Liver Fibrosis Assessment by Route of Administration
- Liver Fibrosis Assessment by Stage and Route of Administration
- Liver Fibrosis Assessment by Molecule Type
- Liver Fibrosis Assessment by Stage and Molecule Type
- Liver Fibrosis Therapeutics – Discontinued Products
- Liver Fibrosis Therapeutics – Dormant Products
- Products under Development by Companies, 2014

List of Figures

- Number of Products under Development for Liver Fibrosis, 2014
- Late Clinical Stage Products (Filed and Phase III), 2014
- Mid Clinical Stage Products (Phase II), 2014
- Early Clinical Stage Products (Phase I and IND Filed), 2014
- Discovery and Pre-Clinical Stage Products, 2014
- Liver Fibrosis Assessment by Monotherapy Products
- Liver Fibrosis Assessment by Combination Products
- Liver Fibrosis Assessment by Route of Administration
- Liver Fibrosis Assessment by Stage and Route of Administration
- Liver Fibrosis Assessment by Molecule Type
- Liver Fibrosis Assessment by Stage and Molecule Type

To order this report: Liver Fibrosis-Pipeline Insights, 2014
http://www.reportlinker.com/p02278629/-Liver-Fibrosis-Pipeline-Insights-2014.html
__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001


'/>"/>

SOURCE Reportlinker
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Liver Transplantation-Pipeline Insights, 2014
2. BioDelivery Sciences to Ring The NASDAQ Stock Market Opening Bell
3. Needle-Free Delivery Devices Shape the Future of Vaccines, Says Frost & Sullivan
4. Needle-Free Delivery: Technology and Market Forecast 2014-2024
5. Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org
6. Global Intranasal Drug Delivery Market 2014-2018: Key Vendors are Becton, Dickinson and Company, GlaxoSmithKline, Johnson & Johnson and Novartis
7. Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients
8. ResMeds New AirSense 10 CPAP and APAP Devices Deliver Superior Patient Comfort and Cost-Saving Efficiency for Healthcare Providers
9. Coloplast Delivers On Ambitious Targets With Solid Interim Report
10. Organovo Highlights Liver Toxicology Achievement, Reports Q1 Fiscal 2015 Results
11. BioDelivery Sciences Announces BEMA Buprenorphine NDA Submission on Track following Pre-NDA Meeting with FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... -- AllianceRx Walgreens Prime, the combined central specialty pharmacy and ... manager Prime Therapeutics LLC (Prime), today officially began the ... of new signage at its headquarters in ... few other company-owned facilities across the country. This also ... whom will begin to see the AllianceRx Walgreens Prime ...
(Date:9/27/2017)... MIAMI , Sept. 27, 2017  Commended for their ... recent notable awards. Ranked as number one in the South ... ninth time in Inc. 5000 yearly list, the national specialty ... CEO, Armando Bardisa will soon be honored by ... Set to receive his award ...
(Date:9/22/2017)... , Sept. 22, 2017  As the latest ... Senators Bill Cassidy (R-LA) and Lindsey ... notes that the medical device industry is in an ... device tax, the 2.3% excise tax on medical device ... they also want covered patients, increased visits and hospital ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a missionary ... Journey: From the Mountains to the Mission Field” is the creation of published author, ... ages and currently teaches a class of ladies at her church, which she has ...
(Date:10/12/2017)... ... 2017 , ... Planet Fitness, one of the largest and fastest growing franchisors ... a flagship location in Covington, LA at 401 N. U.S. Highway 190, in January ... Office Depot in the Holiday Square shopping center. Its location allows it to serve ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally recognized health ... expanded their existing home health joint venture through an agreement, effective October 1, ... joint venture home health company with Asante, delivering clinically integrated care, for the ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... for the 49th Congress of the International Society of Paediatric Oncology (SIOP) ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. ...
(Date:10/12/2017)... ... , ... In the United States, single-family home owners pay ... York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the average is $7,000 a ... rates, which contributes to the relatively lower cost of living in places like ...
Breaking Medicine News(10 mins):